Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 18;6(1):19-20.
eCollection 2017.

HSD11B1 rs846908 Polymorphisms and Tacrolimus Concentrations: Quantum Chemical Analysis and Implication in Patients With Renal Transplantation

Affiliations
Free PMC article

HSD11B1 rs846908 Polymorphisms and Tacrolimus Concentrations: Quantum Chemical Analysis and Implication in Patients With Renal Transplantation

Beuy Joob et al. J Nephropharmacol. .
Free PMC article

Abstract

No abstract available

Keywords: Kidney; Polymorphism; Tacrolimus; Transplantation.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Wong CJ, Pagalilauan G. Primary Care of the Solid Organ Transplant Recipient. Med Clin North Am. 2015;99:1075–103. - PubMed
    1. Garnock-Jones KP. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients. Drugs. 2015;75:309–20. - PubMed
    1. Hronová K, Šíma M, Světlík S, Matoušková O, Slanař O. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol. 2014;7:821–35. - PubMed
    1. Liu X, Li J, Fu Q, Liu S, Zhang Y, Wang X. et al. Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. Drug Metab Dispos. 2015;43:455–8. - PubMed
    1. Wiwanitkit V. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: an explanation for variation in imatinib effect in mutated type. Indian J Cancer. 2009;46:335–6. - PubMed

LinkOut - more resources

Feedback